Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -31.89% |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.89% |
| Mar 31, 2026 | 65.80% |
| Dec 31, 2025 | 241.26% |
| Sep 30, 2025 | -109.29% |
| Jun 30, 2025 | 124.42% |
| Mar 31, 2025 | 63.52% |
| Dec 31, 2024 | 219.81% |
| Sep 30, 2024 | -124.85% |
| Jun 30, 2024 | -881.20% |
| Mar 31, 2024 | -28.40% |
| Dec 31, 2023 | -202.85% |
| Sep 30, 2023 | 611.91% |
| Jun 30, 2023 | -41.03% |
| Mar 31, 2023 | 3.03% |
| Dec 31, 2022 | 114.34% |
| Sep 30, 2022 | 65.69% |
| Jun 30, 2022 | -70.48% |
| Mar 31, 2022 | -98.63% |
| Dec 31, 2021 | -160.27% |
| Sep 30, 2021 | 63.46% |